Abstract
When lung cancer is detected, in the majority of cases it cannot be effectively treated and the patient will die of the disease. At presentation, most thoracic tumors are currently staged as nonresectable (1). This factor, coupled with the relative resistance of the disease to chemotherapeutic agents, leads to the high mortality rate. There are therefore two clear ways in which this situation might be improved: first, enhanced diagnostic strategies might allow detection of the disease at a stage when conventional treatment is more effective, and second, improved therapeutic agents would result directly in higher cure rates.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Bulzebruck, H., Bopp, R., Drings, P., Bauer, E., Krysa, S., Probst, G., et al. (1992) New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer 70, 1102–1110.
Henschke, C. I., McCauley, D. I., Yankelevitz, D. F., Naidich, D. P., McGuinness, G., Miettinen, O. S., et al. (1999) Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 354, 99–105.
Sone, S., Takashima, S., Li, F., Yang, Z., Honda, T., Maruyama, Y., et al. (1998) Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 351, 1242–1245.
Huang, S. and Ingber, D. E. (1999) The structure and mechanical complexity of cell-growth control. Nature Cell Biol. 1, E131–E138.
Tockman, M. S., Mulshine, J. L., Piantadosi, S., Erozan, Y. S., Gupta, P. K., Ruckdeschel, J. C., et al. (1997) Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin. Cancer Res. 3, 2237–2246.
Fielding, P., Turnbull, L., Prime, W., Walshaw, M., and Field, J. K. (1999) Heterogeneous nuclear ribonucleoprotein A2/B1 up-regulation in bronchial lavage specimens: A clinical marker of early lung cancer detection. Clin. Cancer Res. 5, 4048–4052.
Miozzo, M., Sozzi, G., Musso, K., Pilotti, S., Incarbone, M., Pastorino, U., and Pierotti, M. A. (1996) Microsatellite alterations in bronchial and sputum specimens of lung cancer patients. Cancer Res. 56, 2285–2288.
Palmisano, W. A., Divine, K. K., Saccomanno, G., Gilliland, F. D., Baylin, S. B., Herman, J. G., and Belinsky, S. A. (2000) Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60, 5954–5958.
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511.
Bittner, M., Meltzer, P., Chen, Y., Jiang, Y., Seftor, E., Hendrix, M., et al. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536–540.
Celis, J. E., Kruhoffer, M., Gromova, I., Frederiksen, C., Ostergaard, M., Thykjaer, T., et al. (2000) Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics. FEBS Lett. 480, 2–16.
Schuuring, E., van Damme, H., Schuuring-Scholtes, E., Verhoeven, E., Michalides, R., Geelen, E., et al. (1998) Characterization of the EMS1 gene and its product, human Cortactin. Cell Adhes. Commun. 61, 85–209.
Sherr, C. J. (1996) Cancer cell cycles. Science 274, 1672–1677.
Betticher, D. C., Heighway, J., Haselton, P. S., Altermatt, H. J., Ryder, W. D. J., Ceerny, T., and Thatcher, N. (1996) Prognostic significance of CCND1 (cyclin D1) overexpression in lung cancer. Br. J. Cancer 73, 294–300.
Betticher, D. C., Heighway, J., Thatcher, N., and Haselton, P. S. (1997) Abnormal expression of CCND1 and RB1 in resection margin epithelia of lung cancer patients. Br. J. Cancer 75, 1761–1768.
Dhar, K. K., Branigan, K., Parkes, J., Howells, R. E. J., Hand, P., Musgrove, C., et al. (1999) Expression and subcellular localisation of cyclin D1 protein in ovarian epithelial tumour cells. Br. J. Cancer 81, 1174–1181.
White, G. R. M., Varley, J. M., and Heighway, J. (2000) Genomic structure and expression profile of LPHH1, a 7TM gene variably expressed in breast cancer cell lines. BBA Gene Struct. Expr. 1491, 75–92.
White, R. M. G., Stack, M. T., Santibanez-Koref, M. F., Liscia, D. S., Venesio, T., Wang, J. C., et al. (1996) Elevated levels of loss at the 17p telomere suggest the close proximity of a tumour suppressor. Br. J. Cancer 74, 863–870.
Heighway, J. (1991) PCR primers to convert c-Ki-ras into a four allele RasI system. Nucleic Acids Res. 19, 6966.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Heighway, J., Betticher, D., Knapp, T., Hoban, P. (2003). Comparative Multiplex PCR and Allele-Specific Expression Analysis in Human Lung Cancer. In: Driscoll, B. (eds) Lung Cancer. Methods in Molecular Medicine™, vol 75. Humana Press, Totowa, NJ. https://doi.org/10.1385/1-59259-324-0:291
Download citation
DOI: https://doi.org/10.1385/1-59259-324-0:291
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-0-89603-920-9
Online ISBN: 978-1-59259-324-8
eBook Packages: Springer Protocols